Professor Hing Leung

Professor of Urology and Surgical Oncology (Clinical Research Garscube)
Director of Innovation, Engagement and Enterprise (School of Cancer Sciences)

email: h.leung@crukscotlandinstitute.ac.uk

Beatson Institute, Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1BD

Research interests

Prostate cancer (PC) is a major global health issue, and its management remains controversial. A refined understanding of how aberrant signaling drives prostate carcinogenesis will help develop better prognostic biomarkers and therapeutic targets. FGF receptor and ERK5 are signaling molecules implicated in clinical PC. Work in our laboratory continues to explore the significance of these signaling pathways of interest, and to apply in vitro and in vivo models to investigate tumour biology and to develop specific small molecule inhibitors. Working closely with colleagues in National Health Service, Glasgow University and the Institute, we are developing infrastructure required for the necessary biorespository and other ongoing translational research programmes.

Link to Urology Research website

Research groups

Cancer Evolution in Time & Space
Immunology & Cancer
Health Inequalities to Cancer Outcomes
Prostate

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001

Number of items: 167.

2024

Keith, N. et al. (2024) Emerging Ecologies of Health, Heritage, and Habitat: Looking into Living and Working in 2033. [Exhibitions]

Sahni, D. S., Morrison, J. and Leung, H. Y. (2024) Grid-based cognitive diagnostic prostatic biopsies without transrectal ultrasound imaging. BJU International, (doi: 10.1111/bju.16396) (PMID:38740562) (Early Online Publication)

Dehghani, P., Karthikeyan, V. , Tajabadi, A., Assi, D. S., Catchpole, A., Wadsworth, J., Leung, H. Y. and Roy, V. A.L. (2024) Rapid near-patient impedimetric sensing platform for prostate cancer diagnosis. ACS Omega, 9(12), pp. 14580-14591. (doi: 10.1021/acsomega.4c00843) (PMID:38560003) (PMCID:PMC10976404)

2023

Taggart, R., Dutto, L., Leung, H. Y. , Salji, M. and Ahmad, I. (2023) A contemporary analysis of disease upstaging of Gleason 3+3 prostate cancer patients after Robot-Assisted Laparoscopic Prostatectomy (RALP). Cancer Medicine, 12(22), pp. 20830-20837. (doi: 10.1002/cam4.6651) (PMID:3792988) (PMCID:PMC10709727)

Tibbo, A. J., Hartley, A., Vasan, R. , Shaw, R., Galbraith, L., Mui, E., Leung, H. Y. and Ahmad, I. (2023) MBTPS2 acts as a regulator of lipogenesis and cholesterol synthesis through SREBP signalling in prostate cancer. British Journal of Cancer, 128(11), pp. 1991-1999. (doi: 10.1038/s41416-023-02237-7) (PMID:36991255) (PMCID:PMC10205813)

Sandilands, E. et al. (2023) The small GTPase ARF3 controls invasion modality and metastasis by regulating N-cadherin levels. Journal of Cell Biology, 222(4), e202206115. (doi: 10.1083/jcb.202206115) (PMID:36880595) (PMCID:PMC9997661)

AlRasheedi, M., Han, S. , Thygesen, H., Neilson, M., Hendry, F., Alkarn, A., Maclay, J. D. and Leung, H. Y. (2023) A comparative evaluation of mediastinal nodal SUVmax and derived ratios from 18F-FDG PET/CT imaging to predict nodal metastases in non-small cell lung cancer. Diagnostics, 13(7), 1209. (doi: 10.3390/diagnostics13071209) (PMID:37046427) (PMCID:PMC10093125)

Bennett, S. S., Leung, H. Y. and Ahmad, I. (2023) A cohort analysis of patients receiving neoadjuvant androgen deprivation therapy prior to robot-assisted laparoscopic prostatectomy during the Covid-19 pandemic. Journal of Clinical Urology, 16(2), pp. 13-139. (doi: 10.1177/20514158211022216)

Román-Fernández, A. et al. (2023) Spatial regulation of the glycocalyx component podocalyxin is a switch for prometastatic function. Science Advances, 9(5), eabq1858. (doi: 10.1126/sciadv.abq1858) (PMID:36735782) (PMCID:PMC9897673)

Rushworth, L. K. et al. (2023) Phase II proof of concept study of atorvastatin in castration resistant prostate cancer. BJU International, 131(2), pp. 236-243. (doi: 10.1111/bju.15851) (PMID:35844167) (PMCID:PMC10087532)

2022

Freckmann, E. C. et al. (2022) Traject3d allows label-free identification of distinct co-occurring phenotypes within 3D culture by live imaging. Nature Communications, 13, 5317. (doi: 10.1038/s41467-022-32958-x) (PMID:36085324) (PMCID:PMC9463449)

Patel, R. et al. (2022) Cyclocreatine suppresses creatine metabolism and impairs prostate cancer progression. Cancer Research, 82(14), pp. 2565-2575. (doi: 10.1158/0008-5472.CAN-21-1301) (PMID:35675421) (PMCID:PMC9381098)

Sooriakumaran, P. et al. (2022) Feasibility and safety of radical prostatectomy for oligo‐metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo‐Metastases to the bone (TRoMbone) trial. BJU International, 130(1), pp. 43-53. (doi: 10.1111/bju.15669) (PMID:34878715)

Salji, M. J. et al. (2022) Multi-omics and pathway analysis identify potential roles for tumour n-acetyl aspartate accumulation in murine models of castration resistant prostate cancer. iScience, 25(4), 104056. (doi: 10.1016/j.isci.2022.104056) (PMID:35345457) (PMCID:PMC8957019)

Gómez, V. et al. (2022) HER2 mediates PSMA/mGluR1-driven resistance to the DS-7423 dual PI3K/mTOR inhibitor in PTEN wild-type prostate cancer models. Molecular Cancer Therapeutics, 21(4), pp. 667-676. (doi: 10.1158/1535-7163.mct-21-0320) (PMID:35086953) (PMCID:PMC7612588)

Gaba, F., Tipping, W. J., Salji, M. , Faulds, K., Graham, D. and Leung, H. Y. (2022) Raman spectroscopy in prostate cancer: techniques, applications and advancements. Cancers, 14(6), 1535. (doi: 10.3390/cancers14061535) (PMID:35326686) (PMCID:PMC8946151)

Blomme, A. et al. (2022) THEM6‐mediated reprogramming of lipid metabolism supports treatment resistance in prostate cancer. EMBO Molecular Medicine, 14(3), e14764. (doi: 10.15252/emmm.202114764) (PMID:35014179) (PMCID:PMC8899912)

Adam, C., Bray, T. L., Pérez-López, A. M., Tan, E. H., Rubio-Ruiz, B., Baillache, D. J., Houston, D. R., Salji, M. J. , Leung, H. Y. and Unciti-Broceta, A. (2022) A 5-FU precursor designed to evade anabolic and catabolic drug pathways and activated by Pd chemistry in vitro and in vivo. Journal of Medicinal Chemistry, 65(1), pp. 552-561. (doi: 10.1021/acs.jmedchem.1c01733) (PMID:34979089)

2021

Stonier, T. et al. (2021) The "Is mpMRI Enough" or IMRIE Study: a multicentre evaluation of prebiopsy multiparametric magnetic resonance imaging compared with biopsy. European Urology Focus, 7(5), pp. 1027-1034. (doi: 10.1016/j.euf.2020.09.012) (PMID:33046412)

Martinez, R. S. et al. (2021) SLFN5 regulates LAT1-mediated mTOR activation in castration-resistant prostate cancer. Cancer Research, 81(13), pp. 3664-3678. (doi: 10.1158/0008-5472.CAN-20-3694) (PMID:33985973)

Ntala, C. et al. (2021) Analysis of prostate cancer tumor microenvironment identifies reduced stromal CD4 effector T-cell infiltration in tumors with pelvic nodal metastasis. European Urology Open Science, 29, pp. 19-29. (doi: 10.1016/j.euros.2021.05.001) (PMID:34337530) (PMCID:PMC8317840)

Cangiano, M. et al. (2021) Gene regulation network analysis on human prostate orthografts highlights a potential role for the JMJD6 regulon in clinical prostate cancer. Cancers, 13(9), 2094. (doi: 10.3390/cancers13092094) (PMID:33925994) (PMCID:PMC8123677)

Galbraith, L. C.A., Mui, E., Nixon, C., Hedley, A., Strachan, D., MacKay, G., Sumpton, D., Sansom, O. J. , Leung, H. Y. and Ahmad, I. (2021) PPAR-gamma induced AKT3 expression increases levels of mitochondrial biogenesis driving prostate cancer. Oncogene, 40(13), pp. 2355-2366. (doi: 10.1038/s41388-021-01707-7) (PMID:33654198) (PMCID:PMC8016665)

Nacke, M. et al. (2021) An ARF GTPase module promoting invasion and metastasis through regulating phosphoinositide metabolism. Nature Communications, 12, 1623. (doi: 10.1038/s41467-021-21847-4) (PMID:33712589) (PMCID:PMC7955138)

Laskar, P., Somani, S., Mullin, M., Tate, R. J., Warzecha, M., Bowering, D., Keating, P., Irving, C., Leung, H. Y. and Dufès, C. (2021) Octadecyl chain-bearing PEGylated poly(propyleneimine)-based dendrimersomes: physicochemical studies, redox-responsiveness, DNA condensation, cytotoxicity and gene delivery to cancer cells. Biomaterials Science, 9(4), pp. 1431-1448. (doi: 10.1039/D0BM01441A) (PMID:33404026)

Hartley, A., Leung, H. Y. and Ahmad, I. (2021) Targeting the BAF complex in advanced prostate cancer. Expert Opinion on Drug Discovery, 16(2), pp. 173-181. (doi: 10.1080/17460441.2020.1821644) (PMID:32936685)

2020

McAllister, M. J., McCall, P., Dickson, A., Underwood, M. A., Andersen, D., Holmes, E., Market, E., Leung, H. Y. and Edwards, J. (2020) Androgen receptor phosphorylation at serine 81 and serine 213 in castrate-resistant prostate cancer. Prostate Cancer and Prostatic Diseases, 23(4), pp. 596-606. (doi: 10.1038/s41391-020-0235-1) (PMID:32358577)

Malviya, G. et al. (2020) 18F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy. EJNMMI Research, 10, 143. (doi: 10.1186/s13550-020-00728-9) (PMID:33237350) (PMCID:PMC7688773)

McAllister, M., Constancio, V., Patek, S., Gan, H., Bailey, P. , Wheadon, H. , Underwood, M., Leung, H. and Edwards, J. (2020) Inflammatory infiltration is associated with AR expression and poor prognosis in hormone naïve prostate cancer. Prostate, 80(15), pp. 1353-1364. (doi: 10.1002/pros.24064) (PMID:32846021)

Mevel, R. et al. (2020) RUNX1 marks a luminal castration-resistant lineage established at the onset of prostate development. eLife, 9, e60225. (doi: 10.7554/elife.60225) (PMID:33025905) (PMCID:PMC7644213)

Pritchard, J. J.G., Hamilton, G., Hurst, C. D., Fraser, S., Orange, C., Knowles, M. A., Jones, R. J. , Leung, H. Y. and Iwata, T. (2020) Monitoring of urothelial cancer disease status after treatment by digital droplet PCR liquid biopsy assays. Urologic Oncology: Seminars and Original Investigations, 38(9), 731.e1-737.e10. (doi: 10.1016/j.urolonc.2020.05.012) (PMID:32532529)

Blomme, A. et al. (2020) 2,4-dienoyl-CoA reductase regulates lipid homeostasis in treatment-resistant prostate cancer. Nature Communications, 11, 2508. (doi: 10.1038/s41467-020-16126-7) (PMID:32427840) (PMCID:PMC7237503)

Scarsbrook, A. F. et al. (2020) Effect of 18F-fluciclovine positron emission tomography on the management of patients with recurrence of prostate cancer: Results from the FALCON Trial. International Journal of Radiation Oncology, Biology, Physics, 107(2), pp. 316-324. (doi: 10.1016/j.ijrobp.2020.01.050) (PMID:32068113)

Neal, D. E. et al. (2020) Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT Randomised Controlled Trial according to treatment received. European Urology, 77(3), pp. 320-330. (doi: 10.1016/j.eururo.2019.10.030) (PMID:31771797)

Rushworth, L. K., Hewit, K., Munnings-Tomes, S., Somani, S., James, D., Shanks, E., Dufès, C., Straube, A., Patel, R. and Leung, H. Y. (2020) Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment. British Journal of Cancer, 122, pp. 517-527. (doi: 10.1038/s41416-019-0681-5) (PMID:31844184) (PMCID:PMC7028732)

Patel, R. et al. (2020) Activation of β-catenin cooperates with loss of Pten to drive AR-independent castration-resistant prostate cancer. Cancer Research, 80(3), pp. 576-590. (doi: 10.1158/0008-5472.CAN-19-1684) (PMID:31719098)

Loveridge, C. J. et al. (2020) BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration. Oncogene, 39, pp. 1797-1806. (doi: 10.1038/s41388-019-1106-x) (PMID:31740786) (PMCID:PMC7033044)

2019

Birrell, F. and Leung, H. Y. (2019) The Scottish prostate cryotherapy service-the role of the clinical nurse specialist. British Journal of Nursing, 28(18), S12-S16. (doi: 10.12968/bjon.2019.28.18.S12) (PMID:31597067)

McAllister, M. J., Underwood, M. A., Leung, H. Y. and Edwards, J. (2019) A review on the interactions between the tumour microenvironment and androgen receptor signaling in prostate cancer. Translational Research, 206, pp. 91-106. (doi: 10.1016/j.trsl.2018.11.004) (PMID:30528321)

Kdadra, M., Höckner, S., Leung, H. , Kremer, W. and Schiffer, E. (2019) Metabolomics biomarkers of prostate cancer: A systematic review. Diagnostics, 9(1), 21. (doi: 10.3390/diagnostics9010021) (PMID:30791464) (PMCID:PMC6468767)

2018

Laskar, P., Somani, S., Altwaijry, N., Mullin, M., Bowering, D., Warzecha, M., Keating, P., Tate, R. J., Leung, H. Y. and Dufès, C. (2018) Redox-sensitive, cholesterol-bearing PEGylated poly(propylene imine)-based dendrimersomes for drug and gene delivery to cancer cells. Nanoscale, 2018(10), pp. 22830-22847. (doi: 10.1039/c8nr08141g) (PMID:30488937)

Salji, M. , Hendry, J., Patel, A., Ahmad, I. , Nixon, C. and Leung, H. Y. (2018) Peri-prostatic fat volume measurement as a predictive tool for castration resistance in advanced prostate cancer. European Urology Focus, 4(6), pp. 858-866. (doi: 10.1016/j.euf.2017.01.019) (PMID:28753854) (PMCID:PMC6314965)

Hewit, K., Sandilands, E., Sanchez Martinez, R., James, D., Leung, H. Y. , Bryant, D. M. , Shanks, E. and Markert, E. K. (2018) A functional genomics screen reveals a strong synergistic effect between docetaxel and the mitotic gene DLGAP5 that is mediated by the androgen receptor. Cell Death and Disease, 9(11), 1069. (doi: 10.1038/s41419-018-1115-7) (PMID:30341281) (PMCID:PMC6195526)

Bray, T. L., Salji, M. , Brombin, A., Pérez-López, A. M., Rubio-Ruiz, B., Galbraith, L. C.A., Patton, E. E., Leung, H. Y. and Unciti-Broceta, A. (2018) Bright insights into palladium-triggered local chemotherapy. Chemical Science, 9(37), pp. 7354-7361. (doi: 10.1039/c8sc02291g) (PMID:30542538) (PMCID:PMC6237126)

Galbraith, L., Leung, H. Y. and Ahmad, I. (2018) Lipid pathway deregulation in advanced prostate cancer. Pharmacological Research, 131, pp. 177-184. (doi: 10.1016/j.phrs.2018.02.022) (PMID:29466694)

Patel, R. et al. (2018) Sprouty2 loss‐induced IL6 drives castration‐resistant prostate cancer through scavenger receptor B1. EMBO Molecular Medicine, 10(4), e8347. (doi: 10.15252/emmm.201708347) (PMID:29540470) (PMCID:PMC5887544)

Altwaijry, N., Somani, S., Parkinson, J. A., Tate, R. J., Keating, P., Warzecha, M., Mackenzie, G. R., Leung, H. Y. and Dufès, C. (2018) Regression of prostate tumors after intravenous administration of lactoferrin-bearing polypropylenimine dendriplexes encoding TNF-α, TRAIL, and interleukin-12. Drug Delivery, 25(1), pp. 679-689. (doi: 10.1080/10717544.2018.1440666) (PMID:29493296) (PMCID:PMC6058574)

2017

Loveridge, C. J. et al. (2017) Analysis of Nkx3.1:Cre-driven Erk5 deletion reveals a profound spinal deformity which is linked to increased osteoclast activity. Scientific Reports, 7, 13241. (doi: 10.1038/s41598-017-13346-8) (PMID:29038439) (PMCID:PMC5643304)

Munkley, J. et al. (2017) The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. Oncotarget, 6(33), pp. 34358-34374. (doi: 10.18632/oncotarget.6024) (PMID:26452038) (PMCID:PMC4741458)

Munkley, J. et al. (2017) The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration. Scientific Reports, 7, 5249. (doi: 10.1038/s41598-017-05489-5) (PMID:28701765) (PMCID:PMC5507901)

Loveridge, C. J. et al. (2017) Increased T cell infiltration elicited by Erk5 deletion in a Pten-deficient mouse model of prostate carcinogenesis. Cancer Research, 77(12), pp. 3158-3168. (doi: 10.1158/0008-5472.CAN-16-2565) (PMID:28515147)

Rewhorn, M.J., Baxter, G. and Leung, H.Y. (2017) Delayed fistula post-salvage prostate cryotherapy. Journal of Clinical Urology, 10(3), pp. 189-190. (doi: 10.1177/2051415814565201)

Kerr, L., Leung, H. Y. , Melquiot, N., Arestis, N. and Sidek, N. (2017) Lymphoma masquerading as advanced prostate cancer with lymphadenopathy. Journal of Clinical Urology, 10(3), pp. 174-176. (doi: 10.1177/2051415814560081)

2016

Lane, A. et al. (2016) Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. BJU International, 118(6), pp. 869-879. (doi: 10.1111/bju.13582) (PMID:27415448) (PMCID:PMC5113698)

Patek, S.C., Willder, J.M., Heng, J.S., Taylor, B., Horgan, P.G. , Leung, H.Y. , Underwood, M.A. and Edwards, J. (2016) Androgen receptor phosphorylation status at serine 578 predicts poor outcome in prostate cancer patients. Oncotarget, 8(3), pp. 4875-4887. (doi: 10.18632/oncotarget.13608) (PMID:27902483)

Salji, M., Payne, S., Fraser, S., Lamb, C., Wallace, J., Qureshi, K., Duff, M., Hendry, D. and Leung, H. Y. (2016) Basaloid carcinoma of prostate (BCP) in a patient with previous history of pelvic radiotherapy treated with total pelvic exenteration and abdominoperineal resection. Journal of Clinical Urology, 9(6), pp. 431-433. (doi: 10.1177/2051415814531575)

Mason, M.D. et al. (2016) Radiotherapy for prostate cancer: is it ‘what you do’ or ‘the way that you do it’? A UK perspective on technique and quality assurance. Clinical Oncology, 28(9), e92-e100. (doi: 10.1016/j.clon.2016.05.011) (PMID:27425582)

Myers, S. M. et al. (2016) High-throughput screening and hit validation of extracellular-related kinase 5 (ERK5) inhibitors. ACS Combinatorial Science, 18(8), pp. 444-455. (doi: 10.1021/acscombsci.5b00155) (PMID:27400250)

Kerr, L., Rewhorn, M. J., Longmuir, M., Fraser, S., Walsh, S., Andrew, N. and Leung, H. Y. (2016) A cohort analysis of men with a family history of BRCA1/2 and Lynch mutations for prostate cancer. BMC Cancer, 16, 529. (doi: 10.1186/s12885-016-2573-x) (PMID:27456091) (PMCID:PMC4960816)

Ahmad, I. et al. (2016) Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 113(29), pp. 8290-8295. (doi: 10.1073/pnas.1601571113) (PMID:27357679) (PMCID:PMC4961202)

Munkley, J. et al. (2016) Glycosylation is an androgen-regulated process essential for prostate cancer cell viability. EBioMedicine, 8, pp. 103-116. (doi: 10.1016/j.ebiom.2016.04.018) (PMID:27428423) (PMCID:PMC4919605)

Peck, B. et al. (2016) Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. Cancer and Metabolism, 4(1), 6. (doi: 10.1186/s40170-016-0146-8) (PMID:27042297) (PMCID:PMC4818530)

Klionsky, D. J. et al. (2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 12(1), pp. 1-222. (doi: 10.1080/15548627.2015.1100356) (PMID:26799652) (PMCID:PMC4835977)

2015

Boyd, K. A. , Jones, R. J. , Paul, J. , Birrell, F., Briggs, A. H. and Leung, H. Y. (2015) Decision-analytic cost-effectiveness model to compare prostate cryotherapy to androgen deprivation therapy for treatment of radiation recurrent prostate cancer. BMJ Open, 5(10), e007925. (doi: 10.1136/bmjopen-2015-007925) (PMID:26482768) (PMCID:PMC4611206)

Wade, J. et al. (2015) Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial. BMJ Open, 5(9), e008953. (doi: 10.1136/bmjopen-2015-008953) (PMID:26384727) (PMCID:PMC4577970)

Munkley, J. et al. (2015) The PI3K regulatory subunit gene PIK3R1 is under direct control of androgens and repressed in prostate cancer cells. Oncoscience, 2(9), pp. 755-764. (doi: 10.18632/oncoscience.243) (PMID:26501081) (PMCID:PMC4606009)

Rajan, P., Frew, J. A., Wilson, J. M., Azzabi, A. S.T., McMenemin, R. M., Stockley, J., Soomro, N. A., Durkan, G., Pedley, I. D. and Leung, H. Y. (2015) Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non–castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 33(8), 337.e1-337.e6. (doi: 10.1016/j.urolonc.2015.05.012) (PMID:26092557)

Amin Al Olama, A. et al. (2015) Risk analysis of prostate cancer in PRACTICAL, a multinational consortium, using 25 known prostate cancer susceptibility loci. Cancer Epidemiology, Biomarkers and Prevention, 24(7), pp. 1121-1129. (doi: 10.1158/1055-9965.EPI-14-0317) (PMID:25837820) (PMCID:PMC4491026)

Loveridge, C., Mui, E., Ahmad, I. , Welsh, M., Tan, E., Fleming, J., Sansom, O. and Leung, H. (2015) The Role of Erk5 in Prostate Carcinogenesis. In: 11th World Congress on Urological Research, Nijmegen, The Nertherlands, September 2015, (Unpublished)

Brzezinska, E. A., Nixon, C., Patel, R. and Leung, H. Y. (2015) Genetically engineered mouse models to study prostate cancer. In: Eferl, R. and Casanova, E. (eds.) Mouse Models of Cancer. Series: Methods in Molecular Biology, 1267. Springer, pp. 73-91. (doi: 10.1007/978-1-4939-2297-0_4)

Choudhury, Y., Salt, I. and Leung, H. (2015) AMPK—friend or foe for targeted therapy? Cell Cycle, 14(12), pp. 1761-1762. (doi: 10.1080/15384101.2015.1022066) (PMID:26036305)

Munkley, J., Lafferty, N. P., Kalna, G., Robson, C. N., Leung, H. Y. , Rajan, P. and Elliott, D. J. (2015) Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells. BMC Cancer, 15(9), (doi: 10.1186/s12885-015-1012-8)

Stockley, J., Markert, E., Zhou, Y., Robson, C. N., Elliott, D. J., Lindberg, J., Leung, H. Y. and Rajan, P. (2015) The RNA-binding protein Sam68 regulates expression and transcription function of the androgen receptor splice variant AR-V7. Scientific Reports, 5, 13426. (doi: 10.1038/srep13426) (PMID:26310125) (PMCID:PMC4550848)

2014

Rajan, P. et al. (2014) Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer. BMC Cancer, 14, p. 977. (doi: 10.1186/1471-2407-14-977) (PMID:25519703) (PMCID:PMC4301544)

Rajan, P. and Leung, H. Y. (2014) Experimental urological oncology: Cellular, molecular, and animal. In: Nargund, V. H., Raghavan, D. and Sandler, H. M. (eds.) Urological Oncology. Springer, pp. 39-49. ISBN 9780857294814 (doi: 10.1007/978-0-85729-482-1_2)

Mukherjee, A., Morton, S., Fraser, S., Salmond, J., Baxter, G. and Leung, H. Y. (2014) Magnetic resonance imaging-directed transperineal limited-mapping prostatic biopsies to diagnose prostate cancer: a Scottish experience. Scottish Medical Journal, 59(4), pp. 204-208. (doi: 10.1177/0036933014556197)

Noble-Jones, R., Fitzpatrick, B., Sneddon, M. C., Hendry, D. S. and Leung, H. Y., (2014) Development of the Lymphoedema Genito-Urinary Cancer Questionnaire. British Journal of Nursing, 23(S18), pp. 14-19. (doi: 10.12968/bjon.2014.23.Sup18.S14)

Rajan, P. et al. (2014) Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. European Urology, 66(1), pp. 32-39. (doi: 10.1016/j.eururo.2013.08.011) (PMID:24054872) (PMCID:PMC4062940)

Choudhury, Y., Yang, Z., Ahmad, I. , Nixon, C., Salt, I. P. and Leung, H. Y. (2014) AMP-activated protein kinase (AMPK) as a potential therapeutic target independent of PI3K/Akt signaling in prostate cancer. Oncoscience, 1(6), pp. 446-456. (doi: 10.18632/oncoscience.49) (PMID:25594043) (PMCID:PMC4284621)

Foth, M. et al. (2014) Fibroblast growth factor receptor 3 activation plays a causative role in urothelial cancer pathogenesis in cooperation with Pten loss in mice. Journal of Pathology, 233(2), pp. 148-158. (doi: 10.1002/path.4334)

Stockley, J., Villasevil, M. E. M., Nixon, C., Ahmad, I. , Leung, H. and Rajan, P. (2014) The RNA-binding protein hnRNPA2 regulates β-catenin protein expression and is overexpressed in prostate cancer. RNA Biology, 11(6), pp. 755-765. (doi: 10.4161/rna.28800) (PMID:24823909) (PMCID:PMC4156506)

Boyd, K.A. , Jones, R.J. , Paul, J. , Briggs, A. and Leung, H.Y. (2014) A decision-analytic cost-effectiveness model to compare treatment options for radiation recurrent prostate cancer against androgen deprivation therapy. British Journal of Surgery, 101(s4), p. 59. (doi: 10.1002/bjs.9510)

Li, A. et al. (2014) Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes. Gastroenterology, 146(5), 1386-1396.e17. (doi: 10.1053/j.gastro.2014.01.046) (PMID:24462734) (PMCID:PMC4000441)

Forbat, L., Place, M., Hubbard, G., Leung, H. and Kelly, D. (2014) The role of interpersonal relationships in men's attendance in primary care: qualitative findings in a cohort of men with prostate cancer. Supportive Care in Cancer, 22(2), pp. 409-415. (doi: 10.1007/s00520-013-1989-y)

Munkley, J., Rajan, P., Lafferty, N. P., Dalgliesh, C., Jackson, R. M., Robson, C. N., Leung, H. Y. and Elliott, D. J. (2014) A novel androgen-regulated isoform of the TSC2 tumour suppressor gene increases cell proliferation. Oncotarget, 5(1), pp. 131-139. (doi: 10.18632/oncotarget.1405)

Salji, M., Jones, R. , Paul, J. , Birrell, F., Dixon-Hughes, J., Hutchison, C., Johansen, T.E.B., Greene, D., Parr, N. and Leung, H.Y. (2014) Feasibility study of a randomised controlled trial to compare (deferred) androgen deprivation therapy and cryotherapy in men with localised radiation-recurrent prostate cancer. British Journal of Cancer, 111(3), pp. 424-429. (doi: 10.1038/bjc.2014.316)

2013

Williamson, S.C., Mitter, R., Hepburn, A.C., Wilson, L., Mantilla, A., Leung, H.Y. , Robson, C.N. and Heer, R. (2013) Characterisations of human prostate stem cells reveal deficiency in class I UGT enzymes as a novel mechanism for castration-resistant prostate cancer. British Journal of Cancer, 109(4), pp. 950-956. (doi: 10.1038/bjc.2013.399)

Bennett, H.L., Stockley, J., Fleming, J.T., Mandal, R., O'Prey, J., Ryan, K.M. , Robson, C.N. and Leung, H.Y. (2013) Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells? BJU International, 111(4), pp. 672-682. (doi: 10.1111/j.1464-410X.2012.11409.x)

Patel, R. et al. (2013) Sprouty2, PTEN, and PP2A interact to regulate prostate cancer progression. Journal of Clinical Investigation, 123(3), pp. 1157-1175. (doi: 10.1172/JCI63672)

Forbat, L., Place, M., Kelly, D., Hubbard, G., Boyd, K., Howie, K. and Leung, H.Y. (2013) A cohort study reporting clinical risk factors and individual risk perceptions of prostate cancer: implications for PSA testing. BJU International, 111(3), pp. 389-395. (doi: 10.1111/j.1464-410X.2012.11316.x)

Ahmad, I. , Gao, M., Patel, R. and Leung, H.Y. (2013) Modelling synergistic interactions between HER2, Sprouty2 and PTEN in driving prostate carcinogenesis. Asian Journal of Andrology, 15(3), pp. 323-327. (doi: 10.1038/aja.2013.40)

Ahmad, I., Kalna, G., Ismail, M., Birrell, F., Asterling, S., McCartney, E. , Greene, D., Davies, J. and Leung, H.Y. (2013) Prostate gland lengths and iceball dimensions predict micturition functional outcome following salvage prostate cryotherapy in men with radiation recurrent prostate cancer. PLoS ONE, 8(8), e69243. (doi: 10.1371/journal.pone.0069243) (PMID:23950886) (PMCID:PMC3739755)

Ahmad, I. et al. (2013) Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer. British Journal of Cancer, 108(1), pp. 149-154. (doi: 10.1038/bjc.2012.510)

Neuhaus, J., Schiffer, E., von Wilcke, P., Bauer, H.W., Leung, H., Siwy, J., Ulrici, W., Paasch, U., Horn, L.C. and Stolzenburg, J.U. (2013) Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease. PLoS ONE, 8(6), e67514. (doi: 10.1371/journal.pone.0067514) (PMID:23826311) (PMCID:PMC3691205)

Shafique, K., Proctor, M.J., McMillan, D.C. , Leung, H. , Smith, K., Sloan, B. and Morrison, D.S. (2013) The modified Glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients. BMC Cancer, 13(292), (doi: 10.1186/1471-2407-13-292)

Yang, Z., Laird, A., Monaghan, A., Seywright, M., Ahmad, I. and Leung, H.Y. (2013) Incidental seminal vesicle amyloidosis observed in diagnostic prostate biopsies—are routine investigations for systemic amyloidosis warranted? Asian Journal of Andrology, 15(1), pp. 149-151. (doi: 10.1038/aja.2012.125)

Zhang, T., Watson, D.G., Wang, L., Abbas, M., Murdoch, L., Bashford, L., Ahmad, I., Lam, N.-Y., Ng, A.C.F. and Leung, H.Y. (2013) Application of holistic liquid chromatography-high resolution mass spectrometry based urinary metabolomics for prostate cancer detection and biomarker discovery. PLoS ONE, 8(6), e65880. (doi: 10.1371/journal.pone.0065880) (PMID:23823321) (PMCID:PMC3688815)

2012

Mischak, H. et al. (2012) Implementation of proteomic biomarkers: making it work. European Journal of Clinical Investigation, 42(9), pp. 1027-1036. (doi: 10.1111/j.1365-2362.2012.02674.x) (PMID:22519700) (PMCID:PMC3464367)

Gao, M. et al. (2012) SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis. EMBO Molecular Medicine, 4(8), pp. 776-790. (doi: 10.1002/emmm.201100944)

Krishnan, A., Wilson, J. and Leung, H.Y. (2012) Approaches for developing novel microtubule targeting agents (MTas) for therapeutic exploitation. Current Pharmaceutical Design, 18(19), pp. 2804-2810.

Patel, R. and Leung, H.Y. (2012) Targeting the EGFR-family for therapy: biological challenges and clinical perspective. Current Pharmaceutical Design, 18(19), pp. 2672-2679.

Ahmad, I., Sansom, O.J. and Leung, H.Y. (2012) Exploring molecular genetics of bladder cancer: lessons learned from mouse models. Disease Models and Mechanisms, 5(3), pp. 323-332. (doi: 10.1242/dmm.008888)

Ahmad, I. , Iwata, T. and Leung, H.Y. (2012) Mechanisms of FGFR-mediated carcinogenesis. Biochimica et Biophysica Acta: Molecular Cell Research, 1823(4), pp. 850-860. (doi: 10.1016/j.bbamcr.2012.01.004)

McCall, P. et al. (2012) NFκB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression. British Journal of Cancer, 107(9), pp. 1554-1563. (doi: 10.1038/bjc.2012.372)

Shafique, K., McLoone, P. , Qureshi, K., Leung, H. , Hart, C. and Morrison, D. (2012) Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years' follow up. BMC Cancer, 12(25), (doi: 10.1186/1471-2407-12-25)

Shafique, K., McLoone, P. , Qureshi, K., Leung, H. , Hart, C. and Morrison, D.S. (2012) Tea consumption and the risk of overall and grade specific prostate cancer: a large prospective cohort study of Scottish men. Nutrition and Cancer, 64(6), pp. 790-797. (doi: 10.1080/01635581.2012.690063)

Shafique, K., Proctor, M.J., McMillan, D.C. , Qureshi, K., Leung, H. and Morrison, D.S. (2012) Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer and Prostatic Diseases, 15(2), pp. 195-201. (doi: 10.1038/pcan.2011.60)

Williamson, S.C., Hepburn, A.C., Wilson, L., Coffey, K., Ryan-Munden, C.A., Pal, D., Leung, H.L., Robson, C.N. and Heer, R. (2012) Human α2β1HI CD133+VE epithelial prostate stem cells express low levels of active androgen receptor. PLoS ONE, 7(11), e48944. (doi: 10.1371/journal.pone.0048944) (PMID:23145034) (PMCID:PMC3492135)

2011

Armstrong, K., Ahmad, I. , Kalna, G., Tan, S.S., Edwards, J. , Robson, C.N. and Leung, H.Y. (2011) Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer. British Journal of Cancer, 105(9), pp. 1362-1369. (doi: 10.1038/bjc.2011.367)

Ahmad, I. , Singh, L.B., Foth, M., Morris, C.-A., Taketo, M.M., Wu, X.-R., Leung, H.Y. , Sansom, O.J. and Iwata, T. (2011) K-Ras and β-catenin mutations cooperate with Fgfr3 mutations in mice to promote tumorigenesis in the skin and lung, but not in the bladder. Disease Models and Mechanisms, 4(4), pp. 548-555. (doi: 10.1242/dmm.006874)

Ahmad, I. , Patel, R., Liu, Y., Singh, L.B., Taketo, M.M., Wu, X.-R., Leung, H.Y. and Sansom, O.J. (2011) Ras mutation cooperates with β-catenin activation to drive bladder tumourigenesis. Cell Death and Disease, 2, e124. (doi: 10.1038/cddis.2011.7)

Tan, S.S., Ahmad, I. , Bennett, H.L., Singh, L., Nixon, C., Seywright, M., Barnetson, R.J., Edwards, J. and Leung, H. (2011) GRP78 up-regulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant prostate cance. Journal of Pathology, 223(1), pp. 81-87. (doi: 10.1002/path.2795) (PMID:21125667)

Ahmad, I. et al. (2011) β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene, 30(2), pp. 178-189. (doi: 10.1038/onc.2010.399)

Ahmad, I. et al. (2011) HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 108(39), pp. 16392-16397. (doi: 10.1073/pnas.1101263108)

Chan, F.L. et al. (2011) Identification of novel androgen-regulated pathways and mRNA isoforms through genome-wide exon-specific profiling of the LNCaP transcriptome. PLoS ONE, 6(12), e29088. (doi: 10.1371/journal.pone.0029088) (PMID:22194994) (PMCID:PMC3237596)

Ramsay, A.K. et al. (2011) ERK5 signalling in prostate cancer promotes an invasive phenotype. British Journal of Cancer, 104(4), pp. 664-672. (doi: 10.1038/sj.bjc.6606062)

Shaheen, F.S., Znojek, P., Fisher, A., Webster, M., Plummer, R., Gaughan, L., Smith, G.C. M., Leung, H.Y., Curtin, N.J. and Robson, C.N. (2011) Targeting the DNA double strand break repair machinery in prostate cancer. PLoS ONE, 6(5), e20311. (doi: 10.1371/journal.pone.0020311) (PMID:21629734) (PMCID:PMC3100351)

2010

Wiltshire, C., Singh, B. L., Stockley, J., Fleming, J., Doyle, B., Barnetson, R., Robson, C. N., Kozielski, F. and Leung, H. Y. (2010) Docetaxel-Resistant Prostate Cancer Cells Remain Sensitive to S-Trityl-L-Cysteine-Mediated Eg5 Inhibition. Molecular Cancer Therapeutics, 9(6), pp. 1730-1739. (doi: 10.1158/1535-7163.MCT-09-1103) (PMID:20515952)

Bennett, H.L., Fleming, J.T., O'Prey, J., Ryan, K.M. and Leung, H.Y. (2010) Androgens modulate autophagy and cell death via regulation of the endoplasmic reticulum chaperone glucose-regulated protein 78/BiP in prostate cancer cells. Cell Death and Disease, 1(9), e72. (doi: 10.1038/cddis.2010.50)

Heer, R., Clarke, N., Rigas, A.C., Cheek, T.R., Pickard, R. and Leung, H.Y. (2010) Phenotypic Modulation of Human Urinary Tract Stroma-derived Fibroblasts by Transforming Growth Factor β3. Urology, 76(2), 509.e13. (doi: 10.1016/j.urology.2010.03.018)

2009

Darby, S., Murphy, T., Thomas, H., Robson, C.N., Leung, H.Y. , Mathers, M.E. and Gnanapragasam, V.J. (2009) Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical disease. British Journal of Cancer, 101(11), pp. 1891-1899. (doi: 10.1038/sj.bjc.6605379)

Ramsay, A. and Leung, H. (2009) Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy. Clinical Science, 117(5-6), pp. 209-228. (doi: 10.1042/CS20080391)

Rajan, P., Elliott, D.J., Robson, C.N. and Leung, H.Y. (2009) Alternative splicing and biological heterogeneity in prostate cancer. Nature Reviews Urology, 6(8), pp. 454-460. (doi: 10.1038/nrurol.2009.125)

Thirkettle, H. J., Girling, J., Warren, A. Y., Mills, I. G., Sahadevan, K., Leung, H. , Hamdy, F., Whitaker, H. C. and Neal, D. E. (2009) LYRIC/AEG-1 Is Targeted to Different Subcellular Compartments by Ubiquitinylation and Intrinsic Nuclear Localization Signals. Clinical Cancer Research, 15(9), pp. 3003-3013. (doi: 10.1158/1078-0432.CCR-08-2046)

Ahmad, I. , Sansom, O.J. and Leung, H.Y. (2009) The role of murine models of prostate cancer in drug target discovery and validation. Expert Opinion on Drug Discovery, 4(8), pp. 879-888. (doi: 10.1517/17460440903049308)

Rajan, P. et al. (2009) Proteomic identification of heterogeneous nuclear ribonucleoprotein L as a novel component of SLM/Sam68 nuclear bodies. BMC Cell Biology, 10(1), p. 82. (doi: 10.1186/1471-2121-10-82)

Stevenson, R.D., Ingram, A., Leung, H.Y., McMillan, D.C. and Graham, D. (2009) Quantitative SERRS immunoassay for the detection of human PSA. Analyst, 134(5), pp. 842-844. (doi: 10.1039/B902174D)

Tatarov, O., Mitchell, T.J., Seywright, M., Leung, H.Y. , Brunton, V.G. and Edwards, J. (2009) Src family kinase activity is up-regulated in hormone refractory prostate cancer. Clinical Cancer Research, 15(10), pp. 3540-3549. (doi: 10.1158/1078-0432.CCR-08-1857)

2008

Clark, E. L. et al. (2008) The RNA Helicase p68 Is a Novel Androgen Receptor Coactivator Involved in Splicing and Is Overexpressed in Prostate Cancer. Cancer Research, 68(19), pp. 7938-7946. (doi: 10.1158/0008-5472.CAN-08-0932)

Dovedi, S., Kirby, J., Davies, B., Leung, H. and Kelly, J. (2008) Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma. European Urology, 54(3), pp. 621-630. (doi: 10.1016/j.eururo.2008.01.013)

Rogerson, L., Darby, S., Jabbar, T., Mathers, M.E., Leung, H.Y. , Robson, C.N., Sahadevan, K., OToole, K. and Gnanapragasam, V.J. (2008) Application of transcript profiling in formalin-fixed paraffin-embedded diagnostic prostate cancer needle biopsies. BJU International, 102(3), pp. 364-370. (doi: 10.1111/j.1464-410X.2008.07627.x)

Whitaker, H.C., Girling, J., Warren, A.Y., Leung, H.Y. , Mills, I.G. and Neal, D.E. (2008) Alterations in β‐catenin expression and localization in prostate cancer. Prostate, 68(11), pp. 1196-1205. (doi: 10.1002/pros.20780)

Rajan, P., Gaughan, L., Dalgliesh, C., El-Sherif, A., Robson, C.N., Leung, H.Y. and Elliott, D.J. (2008) Regulation of gene expression by the RNA-binding protein Sam68 in cancer. Biochemical Society Transactions, 36(3), pp. 505-507. (doi: 10.1042/BST0360505)

Rajan, P., Gaughan, L., Dalgliesh, C., El Sherif, A., Robson, C., Leung, H. and Elliott, D. (2008) The RNA-binding and adaptor protein Sam68 modulates signal-dependent splicing and transcriptional activity of the androgen receptor. Journal of Pathology, 215(1), pp. 67-77. (doi: 10.1002/path.2324)

Heer, R., Robson, C.N., Shenton, B.K. and Leung, H.Y. (2008) The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population. Journal of Cellular Physiology, 215(1), pp. 283-284. (doi: 10.1002/jcp.21343)

Ahmad, I. , Sansom, O.J. and Leung, H.Y. (2008) Advances in mouse models of prostate cancer. Expert Reviews in Molecular Medicine, 10, e16. (doi: 10.1017/S1462399408000689)

McCracken, S.R.C., Ramsay, A., Heer, R., Mathers, M.E., Jenkins, B.L., Edwards, J., Robson, C.N., Marquez, R., Cohen, P. and Leung, H.Y. (2008) Aberrant expression of extracellular signal-regulated kinase 5 in human prostate cancer. Oncogene, 27(21), pp. 2978-2988. (doi: 10.1038/sj.onc.1210963)

2007

Edwards, J. and Leung, H.Y. (2007) Editorial comment on: increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. European Urology, 52(6), pp. 1680-1681. (doi: 10.1016/j.eururo.2007.01.098)

Darby, S., Stockley, J., Khan, M.M., Robson, C.N., Leung, H.Y. and Gnanapragasam, V.J. (2007) Expression of GnRH type II is regulated by the androgen receptor in prostate cancer. Endocrine: Related Cancer, 14(3), pp. 613-624. (doi: 10.1677/ERC-07-0041)

Heer, R., Robson, C., Shenton, B. and Leung, H. (2007) The role of androge in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population. Journal of Cellular Physiology, 212(3), pp. 572-578. (doi: 10.1002/jcp.21154)

Sahadevan, K., Darby, S., Leung, H. , Mathers, M., Robson, C. and Gnanapragasam, V. (2007) Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer. Journal of Pathology, 213(1), pp. 82-90. (doi: 10.1002/path.2205)

Dudderidge, T., McCracken, S., Loddo, M., Fanshawe, T., Kelly, J., Neal, D., Leung, H. , Williams, G. and Stoeber, K. (2007) Mitogenic growth signalling, DNA replication licensing, and survival are linked in prostate cancer. British Journal of Cancer, 96(9), pp. 1384-1393. (doi: 10.1038/sj.bjc.6603718)

Jamieson, D., Wilson, K., Pridgeon, S., Margetts, J., Edmondson, R., Leung, H. , Knox, R. and Boddy, A. (2007) NAD(P)H : quinone oxidoreductase1 and NRH : quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH : quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism. Clinical Cancer Research, 13(5), pp. 1584-1590. (doi: 10.1158/1078-0432.CCR-06-1416)

2006

Logan, I., Gaughan, L., McCracken, S., Sapountzi, V., Leung, H. and Robson, C. (2006) Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer. Molecular and Cellular Biology, 26(17), pp. 6502-6510. (doi: 10.1128/MCB.00147-06)

Armstrong, K., Robson, C. and Leung, H. (2006) NF-kappa B activation upregulates fibroblast growth factor 8 expression in prostate cancer cells. Prostate, 66(11), pp. 1223-1234. (doi: 10.1002/pros.20376)

Darby, S., Sahadevan, K., Khan, M., Robson, C., Leung, H. and Gnanapragasam, V. (2006) Loss of Sef (similar expression to FGF) expression is associated with high grade and metastatic prostate cancer. Oncogene, 25(29), pp. 4122-4127. (doi: 10.1038/sj.onc.1209428)

Gnanapragasam, V., Kumar, V., Langton, D., Pickard, R. and Leung, H. (2006) Outcome of transurethral prostatectomy for the palliative management of lower urinary tract symptoms in men with prostate cancer. International Journal of Urology, 13(6), pp. 711-715. (doi: 10.1111/j.1442-2042.2006.01391.x)

Steele, I., Edmondson, R., Leung, H. and Davies, B. (2006) Ligands to FGF receptor 2-IIIb induce proliferation, motility, protection from cell death and cytoskeletal rearrangements in epithelial ovarian cancer cell lines. Growth Factors, 24(1), pp. 45-53. (doi: 10.1080/08977190500361697)

Fong, C. et al. (2006) Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Research, 66(4), pp. 2048-2058. (doi: 10.1158/0008-5472.CAN-05-1072)

2005

Gnanapragasam, V., Darby, S., Khan, M., Lock, W., Robson, C. and Leung, H. (2005) Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer. Journal of Pathology, 206(2), pp. 205-213. (doi: 10.1002/path.1767)

Fernandez-Sanchez, C., McNeil, C., Rawson, K., Nilsson, O., Leung, H. and Gnanapragasam, V. (2005) One-step immunostrip test for the simultaneous detection of free and total prostate specific antigen in serum. Journal of Immunological Methods, 307(01-Feb), pp. 1-12. (doi: 10.1016/j.jim.2005.08.014)

2004

Heer, R., Douglas, D., Mathers, M., Robson, C. and Leung, H. (2004) Fibroblast growth factor 17 is over-expressed in human prostate cancer. Journal of Pathology, 204(5), pp. 578-586. (doi: 10.1002/path.1668)

Zhu, H., Mazor, M., Kawano, Y., Walker, M., Leung, H. , Armstrong, K., Waxman, J. and Kypta, R. (2004) Analysis of Wnt gene expression in prostate cancer: Mutual enhibition by WNT11 and the androgen receptor. Cancer Research, 64(21), pp. 7918-7926. (doi: 10.1158/0008-5472.CAN-04-2704)

Gowardhan, B., West, A., Robson, C.N. and Leung, H.Y. (2004) Adenovirus-mediated expression of a soluble fibroblast growth factor receptor inhibits in vitro growth of prostate DU145 cells. Prostate, 61(1), pp. 50-59. (doi: 10.1002/pros.20067)

Halkidou, K., Gaughan, L., Cook, S., Leung, H. , Neal, D. and Robson, C. (2004) Upregulation and nuclear recruitment of HDACI in hormone refractory prostate cancer. Prostate, 59(2), pp. 177-189. (doi: 10.1002/pros.20022)

Halkidou, K., Cook, S., Leung, H. , Neal, D. and Robson, C. (2004) Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. European Urology, 45(3), pp. 382-389. (doi: 10.1016/j.eururo.2003.10.005)

2003

Gnanapragasam, V., Robinson, M., Marsh, C., Robson, C., Hamdy, F. and Leung, H. (2003) FGF8 isoform b expression in human prostate cancer. British Journal of Cancer, 88(9), pp. 1432-1438. (doi: 10.1038/sj.bjc.6600875)

Halkidou, K., Gnanapragasam, V., Mehta, P., Logan, I., Brady, M., Cook, S., Leung, H. , Neal, D. and Robson, C. (2003) Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene, 22(16), pp. 2466-2477. (doi: 10.1038/sj.onc.1206342)

Drake, M., Robson, W., Mehta, P., Schofield, I., Neal, D. and Leung, H. (2003) An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer. British Journal of Cancer, 88(6), pp. 822-827. (doi: 10.1038/sj.bjc.6600817)

Mehta, P., Jenkins, B., McCarthy, L., Thilak, L., Robson, C., Neal, D. and Leung, H. (2003) MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene, 22(9), pp. 1381-1389. (doi: 10.1038/sj.onc.1206154)

2002

Gowardhan, B., Pedley, I., Robinson, M. and Leung, H. (2002) Late onset classical seminoma in a sib pair with possible familial aetiology. Scandinavian Journal of Urology and Nephrology, 36(5), pp. 383-384. (doi: 10.1080/003655902320783917)

Gnanapragasam, V., Robson, C., Neal, D. and Leung, H. (2002) Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Oncogene, 21(33), pp. 5069-5080. (doi: 10.1038/sj.onc.1205663)

2001

Gnanapragasam, V., Leung, H. , Pulimood, A., Neal, D. and Robson, C. (2001) Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. British Journal of Cancer, 85(12), pp. 1928-1936. (doi: 10.1054/bjoc.2001.2179)

Mehta, P., Robson, C., Neal, D. and Leung, H. (2001) Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells. Oncogene, 20(38), pp. 5359-5365. (doi: 10.1038/sj.onc.1204688)

Djeha, A., Thomson, T., Leung, H. , Searle, P., Young, L., Kerr, D., Harris, P., Mountain, A. and Wrighton, C. (2001) Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: A well-tolerated therapy for established solid tumors. Molecular Therapy, 3(2), pp. 233-240. (doi: 10.1006/mthe.2000.0250)

Steele, I., Edmondson, R., Bulmer, J., Bolger, B., Leung, H. and Davies, B. (2001) Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene, 20(41), pp. 5878-5887. (doi: 10.1038/sj.onc.1204755)

West, A., O'Donnell, M., Charlton, R.G., Neal, D.E. and Leung, H.Y. (2001) Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer. British Journal of Cancer, 85(4), pp. 576-583. (doi: 10.1054/bjoc.2001.1971)

This list was generated on Wed Nov 20 16:40:44 2024 GMT.

Jump to: Articles | Book Sections | Conference Proceedings | Exhibitions